NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Beovu shows Real-World promise for two common eye diseases
Disease control CompletedThis study looked at how well the eye medication Beovu (brolucizumab) works in everyday medical practice for people with wet age-related macular degeneration (AMD) or diabetic macular edema (DME). Researchers observed 572 patients who were already prescribed Beovu by their doctor…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 06:17 UTC
-
Could 3 shots instead of 4 control wet AMD? new study says maybe
Disease control CompletedThis study looked at 742 older adults with wet age-related macular degeneration (nAMD) who had never been treated before. They received three monthly injections of faricimab, a drug that targets two proteins to reduce abnormal blood vessel growth and leakage. The goal was to see …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated May 13, 2026 15:58 UTC